FN2 Earnings Intelligence
Aflac Incorporated earnings overview
Latest Aflac Incorporated (AFL) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Aflac Incorporated
Aflac's Q2 discussion provides partial support for a resilient-demand thesis: U.S. group benefits and new products were growth drivers, while strong capital supports strategic flexibility. Japan premium pressure, higher lapses, and benefit-ratio and macro risks temper the picture.
Aflac Incorporated
Aflac's Q1 2026 results were mixed: revenue of $4.35B beat estimates by 3.4%, but adjusted EPS of $1.75 missed the $1.79 consensus by 2.2%. The revenue beat was driven by a 25.5% surge in Japan sales from new product launches (Miraito cancer, Onsen Tallett medical), though underlying earned premiums in Japan remain flat. U.S. premium growth was modest at 2.9% with persistency at 79.3% and an improved benefit ratio of 47.2%. Management maintained guidance and expressed confidence, highlighting capital strength (ESR 227%, $3.4B liquidity) and $1.3B in shareholder returns. The market reaction was negative, with the stock declining 2.19% (abnormal -3.18% versus benchmark) on roughly 2x normal volume, consistent with investors focusing on the EPS miss and flat premium growth despite the headline sales beat.
Aflac Incorporated
The supplied analysis supports a constructive operating picture: demand for key Japan products and U.S. group offerings is supporting growth, while claims costs, expenses, and earnings volatility temper the outlook.
Aflac Incorporated
The supplied analysis supports a balanced view: Aflac has credible growth drivers in Japan and stable U.S. execution, but the evidence does not yet support an unqualified growth conclusion because earned-premium guidance remains slightly negative and key execution risks remain.
Aflac Incorporated
The supplied analysis supports a constructive but qualified view: Japan product momentum, U.S. persistency and capital returns are supportive, while investment-income volatility, FX exposure and execution risks limit confidence in durable earnings growth.
Aflac Incorporated
The supplied analysis supports a mixed Aflac outlook: Japan earnings strength, high persistency, new products, and strong capital provide support, but U.S. dental weakness, investment-income sensitivity, FX, and commercial-real-estate exposure limit confidence in a uniformly positive trajectory.
Aflac Incorporated
The quarter supports a constructive but conditional view of Aflac: sales expansion, product distribution, and capital strength are positives, while FX, Japan benefit-ratio pressure, and commercial-real-estate exposure temper the outlook.
Aflac Incorporated
The quarter supports a constructive but qualified view: management described stronger underwriting and investment performance, early Tsumitasu traction and improved U.S. execution, while maintaining guidance. The key tests are whether product momentum and expense-ratio gains persist and whether real-estate and FX risks remain contained.
Get the AFL recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.